Dupilumab improves Histologic Remission Rates in EoE Patients

Dupilumab improves histologic remission rates in patients with EOE

Dupilumab results in histologic improvement in patients with eosinophilic esophagitis (EOE).

A team led by Evan S. Dellon, MD, MPH, FACG, professor of medicine and assistant professor of epidemiology, Center for Esophageal Diseases and Sowing, University of North Carolina School of Medicine, analyzed the safety and efficacy of weekly dupilumab. or biweekly dosing compared to placebo in EoE patients.

Dupilumab, currently the only treatment approved by the US Food and Drug Administration (FDA) for EoE, is a fully human monoclonal antibody that blocks interleukin-4 and interleukin-13 signaling, both of which play key roles in the disease.

In the three-part, Phase 3 trial, investigators tested patients 12 years of age and older. Each participant was randomized to receive weekly subcutaneous dupilumab 300 mg or placebo in part A of the study.

Also Read :  Eureka Therapeutics Announces New England Journal of Medicine Publication of Clinical Study Demonstrating GPRC5D as an Active Target for the Treatment of Multiple Myeloma

For Part B, patients were treated with either weekly or biweekly dupilumab 300 mg or placebo.

Patients who completed either part A or B were eligible to continue to part C.

Participants who completed part A were treated with dupilumab 300 mg for up to 52 weeks. Part C is ongoing for those who have completed Part B.

The investigators sought the primary endpoints of histologic remission, defined as a change from baseline in more than 6 eosinophils per high-energy field and Dysphagia Symptom Questionnaire (DSQ) score at 24 weeks.

Results showed that 60% (n = 25) of patients who were treated with dupilumab in part A met the primary endpoint of histologic remission, compared with 5% (n = 2) in the placebo group (difference, 55 percentage points; 95% CI, 40-71; p <0.001).

Also Read :  How Difficult Should Organic Chemistry Be?

Part B results showed that histologic remission occurred in 59% (n = 47) of the weekly dupilumab group, 60% (n = 49) of the biweekly dupilumab group, and 6% (n = 5) of the placebo group (difference) between weekly dupilumab and placebo, 54 percentage points; 95% CI, 41–66; p <0.001; difference between dupilumab and placebo every 2 weeks, 56 percentage points; 95% CI, 43–69). At baseline, the mean DSQ score was 33.6±12.41 in part A and 36.7±11.22 in part B.

However, these scores improved in the weekly dupilumab group compared with placebo, with a difference of –12.32 (95% CI, –19.11 to –5.54) in part A and –9.92 (95% CI, –14.81 to –5.02) in part B. (Both p <0.001). This was not true for dupilumab in the every 2 weeks group (category difference, -0.51; 95% CI, -5.42 to 4.41).

Also Read :  Virus alert, which one is it?

For safety, serious adverse events occurred in 9 patients in both arms of the trial, including 7 in the weekly dupilumab group, 1 in the biweekly group, and 1 in the placebo group. One serious adverse event was also observed in the Part AC group during Part C treatment. This patient was treated with placebo in part A and weekly dupilumab in part C.

“In patients with eosinophilic esophagitis, subcutaneous dupilumab weekly improved histologic findings and reduced disease symptoms,” the authors wrote.

The study, “Dupilumab in adults and adolescents with eosinophilic esophagitis,” was published online. New England Journal of Medicine.


Leave a Reply

Your email address will not be published.